Hancock Jaffe Laboratories (NASDAQ:HJLI) Upgraded at ValuEngine

ValuEngine upgraded shares of Hancock Jaffe Laboratories (NASDAQ:HJLI) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, ValuEngine reports.

Separately, Zacks Investment Research lowered shares of Hancock Jaffe Laboratories from a buy rating to a hold rating in a report on Wednesday, June 26th.

HJLI traded up $0.02 during mid-day trading on Thursday, hitting $1.14. The stock had a trading volume of 2,624 shares, compared to its average volume of 135,245. The business’s fifty day simple moving average is $1.04. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.60 and a quick ratio of 1.60. The firm has a market cap of $16.60 million, a price-to-earnings ratio of -0.61 and a beta of 1.34. Hancock Jaffe Laboratories has a 1-year low of $0.87 and a 1-year high of $3.45.

Hancock Jaffe Laboratories (NASDAQ:HJLI) last posted its earnings results on Thursday, May 9th. The company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.14. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.03 million. Hancock Jaffe Laboratories had a negative net margin of 5,161.19% and a negative return on equity of 302.90%.

A hedge fund recently bought a new stake in Hancock Jaffe Laboratories stock. Jane Street Group LLC acquired a new position in shares of Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 31,692 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.27% of Hancock Jaffe Laboratories as of its most recent SEC filing. 1.10% of the stock is owned by institutional investors.

About Hancock Jaffe Laboratories

Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.

Featured Article: Understanding Specialty Certificates of Deposit

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.